Bill Text: FL S1618 | 2017 | Regular Session | Introduced
Bill Title: Controlled Substances
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2017-03-23 - Withdrawn from further consideration [S1618 Detail]
Download: Florida-2017-S1618-Introduced.html
Florida Senate - 2017 SB 1618
By Senator Artiles
40-01109-17 20171618__
1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; adding CBD (Cannabidiol) to the Schedule
4 I list of controlled substances; providing an
5 effective date.
6
7 Be It Enacted by the Legislature of the State of Florida:
8
9 Section 1. Paragraph (c) of subsection (1) of section
10 893.03, Florida Statutes, is amended to read:
11 893.03 Standards and schedules.—The substances enumerated
12 in this section are controlled by this chapter. The controlled
13 substances listed or to be listed in Schedules I, II, III, IV,
14 and V are included by whatever official, common, usual,
15 chemical, trade name, or class designated. The provisions of
16 this section shall not be construed to include within any of the
17 schedules contained in this section any excluded drugs listed
18 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
19 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
20 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
21 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
22 Anabolic Steroid Products.”
23 (1) SCHEDULE I.—A substance in Schedule I has a high
24 potential for abuse and has no currently accepted medical use in
25 treatment in the United States and in its use under medical
26 supervision does not meet accepted safety standards. The
27 following substances are controlled in Schedule I:
28 (c) Unless specifically excepted or unless listed in
29 another schedule, any material, compound, mixture, or
30 preparation that contains any quantity of the following
31 hallucinogenic substances or that contains any of their salts,
32 isomers, including optical, positional, or geometric isomers,
33 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
34 salts of isomers, homologues, nitrogen-heterocyclic analogs,
35 esters, or ethers, if the existence of such salts, isomers, and
36 salts of isomers is possible within the specific chemical
37 designation or class description:
38 1. Alpha-Ethyltryptamine.
39 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
40 oxazoline).
41 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
42 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
43 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
44 6. Bufotenine.
45 7. Cannabis.
46 8. Cathinone.
47 9. DET (Diethyltryptamine).
48 10. 2,5-Dimethoxyamphetamine.
49 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
50 12. DMT (Dimethyltryptamine).
51 13. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
52 of phencyclidine).
53 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
54 15. N-Ethylamphetamine.
55 16. Fenethylline.
56 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
57 18. Ibogaine.
58 19. LSD (Lysergic acid diethylamide).
59 20. Mescaline.
60 21. Methcathinone.
61 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
62 23. PMA (4-Methoxyamphetamine).
63 24. PMMA (4-Methoxymethamphetamine).
64 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
65 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
66 27. MDA (3,4-Methylenedioxyamphetamine).
67 28. JB-336 (N-Methyl-3-piperidyl benzilate).
68 29. N,N-Dimethylamphetamine.
69 30. Parahexyl.
70 31. Peyote.
71 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
72 analog of phencyclidine).
73 33. Psilocybin.
74 34. Psilocyn.
75 35. Salvia divinorum, except for any drug product approved
76 by the United States Food and Drug Administration which contains
77 Salvia divinorum or its isomers, esters, ethers, salts, and
78 salts of isomers, esters, and ethers, if the existence of such
79 isomers, esters, ethers, and salts is possible within the
80 specific chemical designation.
81 36. Salvinorin A, except for any drug product approved by
82 the United States Food and Drug Administration which contains
83 Salvinorin A or its isomers, esters, ethers, salts, and salts of
84 isomers, esters, and ethers, if the existence of such isomers,
85 esters, ethers, and salts is possible within the specific
86 chemical designation.
87 37. Xylazine.
88 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
89 (Thiophene analog of phencyclidine).
90 39. 3,4,5-Trimethoxyamphetamine.
91 40. Methylone (3,4-Methylenedioxymethcathinone).
92 41. MDPV (3,4-Methylenedioxypyrovalerone).
93 42. Methylmethcathinone.
94 43. Methoxymethcathinone.
95 44. Fluoromethcathinone.
96 45. Methylethcathinone.
97 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
98 yl)phenol) and its dimethyloctyl (C8) homologue.
99 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
100 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
101 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
102 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
103 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
104 naphthoyl)indole).
105 51. BZP (Benzylpiperazine).
106 52. Fluorophenylpiperazine.
107 53. Methylphenylpiperazine.
108 54. Chlorophenylpiperazine.
109 55. Methoxyphenylpiperazine.
110 56. DBZP (1,4-Dibenzylpiperazine).
111 57. TFMPP (Trifluoromethylphenylpiperazine).
112 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
113 Methylenedioxy-N-methylbutanamine).
114 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
115 60. 5-Hydroxy-N-methyltryptamine.
116 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
117 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
118 63. Methyltryptamine.
119 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
120 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
121 66. Tyramine (4-Hydroxyphenethylamine).
122 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
123 68. DiPT (N,N-Diisopropyltryptamine).
124 69. DPT (N,N-Dipropyltryptamine).
125 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
126 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
127 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
128 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
129 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
130 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
131 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
132 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
133 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
134 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
135 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
136 81. Butylone (3,4-Methylenedioxy-alpha
137 methylaminobutyrophenone).
138 82. Ethcathinone.
139 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
140 84. Naphyrone (Naphthylpyrovalerone).
141 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
142 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
143 87. 3,4-Methylenedioxy-propiophenone.
144 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
145 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
146 90. 3,4-Methylenedioxy-N-acetylcathinone.
147 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
148 92. 3,4-Methylenedioxy-N-acetylethcathinone.
149 93. Bromomethcathinone.
150 94. Buphedrone (alpha-Methylamino-butyrophenone).
151 95. Eutylone (3,4-Methylenedioxy-alpha
152 ethylaminobutyrophenone).
153 96. Dimethylcathinone.
154 97. Dimethylmethcathinone.
155 98. Pentylone (3,4-Methylenedioxy-alpha
156 methylaminovalerophenone).
157 99. MDPPP (3,4-Methylenedioxy-alpha
158 pyrrolidinopropiophenone).
159 100. MDPBP (3,4-Methylenedioxy-alpha
160 pyrrolidinobutyrophenone).
161 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
162 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
163 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
164 (Benocyclidine).
165 104. F-MABP (Fluoromethylaminobutyrophenone).
166 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
167 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
168 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
169 108. Me-EABP (Methylethylaminobutyrophenone).
170 109. Etizolam.
171 110. PPP (Pyrrolidinopropiophenone).
172 111. PBP (Pyrrolidinobutyrophenone).
173 112. PVP (Pyrrolidinovalerophenone) or
174 (Pyrrolidinopentiophenone).
175 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
176 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
177 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
178 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
179 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
180 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
181 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
182 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
183 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
184 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
185 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
186 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
187 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
188 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
189 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
190 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
191 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
192 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
193 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
194 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
195 ol).
196 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
197 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
198 methanol).
199 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
200 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
201 1,4-dione).
202 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
203 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
204 undecanamide).
205 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
206 undecanamide).
207 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
208 methyloctan-2-yl)phenol).
209 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
210 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
211 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
212 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
213 methoxyphenylacetyl)indole).
214 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
215 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
216 naphthalenylmethanone).
217 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
218 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
219 naphthalenylmethanone).
220 143. Pentedrone (alpha-Methylaminovalerophenone).
221 144. Fluoroamphetamine.
222 145. Fluoromethamphetamine.
223 146. Methoxetamine.
224 147. Methiopropamine.
225 148. Methylbuphedrone (Methyl-alpha
226 methylaminobutyrophenone).
227 149. APB ((2-Aminopropyl)benzofuran).
228 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
229 151. UR-144 (1-Pentyl-3-(2,2,3,3
230 tetramethylcyclopropanoyl)indole).
231 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
232 tetramethylcyclopropanoyl)indole).
233 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
234 tetramethylcyclopropanoyl)indole).
235 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
236 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
237 iodobenzoyl)indole).
238 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
239 carboxamide).
240 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
241 cyclohexylcarbamate).
242 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
243 cyclohexyl ester).
244 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
245 benzoxazin-4-one).
246 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
247 161. 2C-H (2,5-Dimethoxyphenethylamine).
248 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
249 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
250 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
251 methoxybenzyl)]phenethylamine).
252 165. MDMA (3,4-Methylenedioxymethamphetamine).
253 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
254 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
255 carboxylate).
256 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
257 carboxylate).
258 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
259 3-carboxamide).
260 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
261 pentylindazole-3-carboxamide).
262 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
263 (4-fluorobenzyl)indazole-3-carboxamide).
264 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
265 1-pentylindazole-3-carboxamide).
266 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
267 yl)-1-(fluoropentyl)indole-3-carboxamide).
268 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
269 methoxybenzyl)]phenethylamine).
270 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
271 methoxybenzyl)]phenethylamine).
272 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
273 (cyclohexylmethyl)indazole-3-carboxamide).
274 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
275 carboxylate).
276 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
277 3-carboxamide).
278 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
279 (fluoropentyl)indazole-3-carboxamide).
280 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
281 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
282 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
283 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
284 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
285 hexahydrobenzo[c]chromen-1-ol).
286 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
287 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
288 hexahydrobenzo[c]chromen-1-ol).
289 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
290 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
291 diol).
292 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
293 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
294 tetrahydro-6aH-benzo[c]chromen-1-ol).
295 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
296 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
297 187. MAPB ((2-Methylaminopropyl)benzofuran).
298 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
299 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
300 190. Synthetic Cannabinoids.—Unless specifically excepted
301 or unless listed in another schedule or contained within a
302 pharmaceutical product approved by the United States Food and
303 Drug Administration, any material, compound, mixture, or
304 preparation that contains any quantity of a synthetic
305 cannabinoid found to be in any of the following chemical class
306 descriptions, or homologues, nitrogen-heterocyclic analogs,
307 isomers (including optical, positional, or geometric), esters,
308 ethers, salts, and salts of homologues, nitrogen-heterocyclic
309 analogs, isomers, esters, or ethers, whenever the existence of
310 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
311 ethers, salts, and salts of isomers, esters, or ethers is
312 possible within the specific chemical class or designation.
313 Since nomenclature of these synthetically produced cannabinoids
314 is not internationally standardized and may continually evolve,
315 these structures or the compounds of these structures shall be
316 included under this subparagraph, regardless of their specific
317 numerical designation of atomic positions covered, if it can be
318 determined through a recognized method of scientific testing or
319 analysis that the substance contains properties that fit within
320 one or more of the following categories:
321 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
322 naturally contained in a plant of the genus Cannabis, the
323 synthetic equivalents of the substances contained in the plant
324 or in the resinous extracts of the genus Cannabis, or synthetic
325 substances, derivatives, and their isomers with similar chemical
326 structure and pharmacological activity, including, but not
327 limited to, Delta 9 tetrahydrocannabinols and their optical
328 isomers, Delta 8 tetrahydrocannabinols and their optical
329 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
330 isomers, or any compound containing a tetrahydrobenzo[c]chromene
331 structure with substitution at either or both the 3-position or
332 9-position, with or without substitution at the 1-position with
333 hydroxyl or alkoxy groups, including, but not limited to:
334 (I) Tetrahydrocannabinol.
335 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
336 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
337 ol).
338 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
339 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
340 ol).
341 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
342 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
343 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
344 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
345 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
346 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
347 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
348 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
349 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
350 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
351 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
352 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
353 (X) Parahexyl.
354 b. Naphthoylindoles, Naphthoylindazoles,
355 Naphthoylcarbazoles, Naphthylmethylindoles,
356 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
357 compound containing a naphthoylindole, naphthoylindazole,
358 naphthoylcarbazole, naphthylmethylindole,
359 naphthylmethylindazole, or naphthylmethylcarbazole structure,
360 with or without substitution on the indole, indazole, or
361 carbazole ring to any extent, whether or not substituted on the
362 naphthyl ring to any extent, including, but not limited to:
363 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
364 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
365 naphthoyl)indole).
366 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
367 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
368 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
369 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
370 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
371 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
372 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
373 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
374 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
375 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
376 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
377 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
378 naphthoyl)indole).
379 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
380 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
381 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
382 naphthoyl)indole).
383 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
384 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
385 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
386 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
387 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
388 naphthylmethyl]indole).
389 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
390 naphthoyl)indole).
391 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
392 naphthoyl)indole).
393 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
394 naphthoyl)indole).
395 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
396 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
397 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
398 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
399 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
400 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
401 naphthoyl)indole).
402 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
403 naphthoyl)indole).
404 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
405 naphthoyl)indole).
406 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
407 naphthoyl)indole).
408 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
409 naphthoyl)indole).
410 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
411 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
412 naphthoyl)indazole).
413 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
414 naphthoyl)indole).
415 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
416 naphthoyl)indole).
417 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
418 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
419 naphthoyl)carbazole).
420 c. Naphthoylpyrroles.—Any compound containing a
421 naphthoylpyrrole structure, with or without substitution on the
422 pyrrole ring to any extent, whether or not substituted on the
423 naphthyl ring to any extent, including, but not limited to:
424 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
425 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
426 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
427 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
428 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
429 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
430 naphthoyl)pyrrole).
431 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
432 naphthoyl)pyrrole).
433 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
434 naphthoyl)pyrrole).
435 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
436 naphthoyl)pyrrole).
437 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
438 naphthoyl)pyrrole).
439 d. Naphthylmethylenindenes.—Any compound containing a
440 naphthylmethylenindene structure, with or without substitution
441 at the 3-position of the indene ring to any extent, whether or
442 not substituted on the naphthyl ring to any extent, including,
443 but not limited to, JWH-176 (3-Pentyl-1
444 (naphthylmethylene)indene).
445 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
446 compound containing a phenylacetylindole or phenylacetylindazole
447 structure, with or without substitution on the indole or
448 indazole ring to any extent, whether or not substituted on the
449 phenyl ring to any extent, including, but not limited to:
450 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
451 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
452 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
453 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
454 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
455 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
456 (VII) Cannabipiperidiethanone.
457 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
458 methoxyphenylacetyl)indole).
459 f. Cyclohexylphenols.—Any compound containing a
460 cyclohexylphenol structure, with or without substitution at the
461 5-position of the phenolic ring to any extent, whether or not
462 substituted on the cyclohexyl ring to any extent, including, but
463 not limited to:
464 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
465 yl)phenol).
466 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
467 homologue).
468 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
469 methyloctan-2-yl)phenol).
470 g. Benzoylindoles and Benzoylindazoles.—Any compound
471 containing a benzoylindole or benzoylindazole structure, with or
472 without substitution on the indole or indazole ring to any
473 extent, whether or not substituted on the phenyl ring to any
474 extent, including, but not limited to:
475 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
476 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
477 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
478 iodo-5-nitrobenzoyl)indole).
479 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
480 methoxybenzoyl)indole).
481 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
482 iodobenzoyl)indole).
483 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
484 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
485 methoxybenzoyl)indole).
486 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
487 3-(4-methoxybenzoyl)indole).
488 h. Tetramethylcyclopropanoylindoles and
489 Tetramethylcyclopropanoylindazoles.—Any compound containing a
490 tetramethylcyclopropanoylindole or
491 tetramethylcyclopropanoylindazole structure, with or without
492 substitution on the indole or indazole ring to any extent,
493 whether or not substituted on the tetramethylcyclopropyl group
494 to any extent, including, but not limited to:
495 (I) UR-144 (1-Pentyl-3-(2,2,3,3
496 tetramethylcyclopropanoyl)indole).
497 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
498 tetramethylcyclopropanoyl)indole).
499 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
500 tetramethylcyclopropanoyl)indole).
501 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
502 tetramethylcyclopropanoyl)indole).
503 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
504 tetramethylcyclopropanoyl)indole).
505 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
506 tetramethylcyclopropanoyl)indole).
507 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
508 tetramethylcyclopropanoyl)indole).
509 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
510 tetramethylcyclopropanoyl)indazole).
511 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
512 tetramethylcyclopropanoyl)indole).
513 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
514 tetramethylcyclopropanoyl)indole).
515 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
516 carboxamides, and Adamantylindazole carboxamides.—Any compound
517 containing an adamantoyl indole, adamantoyl indazole, adamantyl
518 indole carboxamide, or adamantyl indazole carboxamide structure,
519 with or without substitution on the indole or indazole ring to
520 any extent, whether or not substituted on the adamantyl ring to
521 any extent, including, but not limited to:
522 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
523 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
524 3-carboxamide).
525 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
526 carboxamide).
527 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
528 adamantoyl)indole).
529 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
530 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
531 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
532 adamantoyl)indole).
533 j. Quinolinylindolecarboxylates,
534 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
535 and Quinolinylindazolecarboxamides.—Any compound containing a
536 quinolinylindole carboxylate, quinolinylindazole carboxylate,
537 isoquinolinylindole carboxylate, isoquinolinylindazole
538 carboxylate, quinolinylindole carboxamide, quinolinylindazole
539 carboxamide, isoquinolinylindole carboxamide, or
540 isoquinolinylindazole carboxamide structure, with or without
541 substitution on the indole or indazole ring to any extent,
542 whether or not substituted on the quinoline or isoquinoline ring
543 to any extent, including, but not limited to:
544 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
545 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
546 carboxylate).
547 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
548 carboxylate).
549 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
550 carboxylate).
551 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
552 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
553 3-carboxylate).
554 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
555 3-carboxylate).
556 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
557 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
558 carboxamide).
559 k. Naphthylindolecarboxylates and
560 Naphthylindazolecarboxylates.—Any compound containing a
561 naphthylindole carboxylate or naphthylindazole carboxylate
562 structure, with or without substitution on the indole or
563 indazole ring to any extent, whether or not substituted on the
564 naphthyl ring to any extent, including, but not limited to:
565 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
566 carboxylate).
567 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
568 carboxylate).
569 (III) Fluoro SDB-005 (1-Naphthalenyl 1
570 (fluoropentyl)indazole-3-carboxylate).
571 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
572 carboxylate).
573 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
574 carboxylate).
575 l. Naphthylindole carboxamides and Naphthylindazole
576 carboxamides.—Any compound containing a naphthylindole
577 carboxamide or naphthylindazole carboxamide structure, with or
578 without substitution on the indole or indazole ring to any
579 extent, whether or not substituted on the naphthyl ring to any
580 extent, including, but not limited to:
581 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
582 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
583 3-carboxamide).
584 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
585 (chloropentyl)indole-3-carboxamide).
586 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
587 carboxamide).
588 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
589 (fluoropentyl)indazole-3-carboxamide).
590 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
591 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
592 Alkylcarbonyl indazole carboxylates.—Any compound containing an
593 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
594 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
595 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
596 indole carboxamide, indazole carboxamide, indole carboxylate, or
597 indazole carboxylate, with or without substitution on the indole
598 or indazole ring to any extent, whether or not substituted on
599 the alkylcarbonyl group to any extent, including, but not
600 limited to:
601 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
602 pentylindole-3-carboxamide).
603 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
604 yl)-1-(fluoropentyl)indole-3-carboxamide).
605 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
606 (fluoropentyl)indole-3-carboxamide).
607 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
608 pentylindazole-3-carboxamide).
609 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
610 1-(fluoropentyl)indazole-3-carboxamide).
611 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
612 1-pentylindazole-3-carboxamide).
613 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
614 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
615 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
616 (4-fluorobenzyl)indazole-3-carboxamide).
617 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
618 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
619 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
620 (cyclohexylmethyl)indazole-3-carboxamide).
621 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
622 (cyclohexylmethyl)indazole-3-carboxamide).
623 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
624 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
625 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
626 pentylindazole-3-carboxamide).
627 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
628 (fluoropentyl)indazole-3-carboxamide).
629 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
630 fluorobenzyl)indazole-3-carboxamide).
631 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
632 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
633 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
634 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
635 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
636 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
637 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
638 fluoropentyl)indole-3-carboxamide).
639 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
640 fluoropentyl)indazole-3-carboxamide).
641 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
642 (cyclohexylmethyl)indazole-3-carboxamide).
643 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
644 fluorobenzyl)indazole-3-carboxamide).
645 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
646 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
647 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
648 Any compound containing a N-(2-phenylpropan-2-yl) indole
649 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
650 structure, with or without substitution on the indole or
651 indazole ring to any extent, whether or not substituted on the
652 phenyl ring of the cumyl group to any extent, including, but not
653 limited to:
654 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
655 carboxamide).
656 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
657 (fluoropentyl)indole-3-carboxamide).
658 o. Other Synthetic Cannabinoids.—Any material, compound,
659 mixture, or preparation that contains any quantity of a
660 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
661 (I) With or without modification or replacement of a
662 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
663 between either two core rings, or linkage between a core ring
664 and group structure, with or without the addition of a carbon or
665 replacement of a carbon;
666 (II) With or without replacement of a core ring or group
667 structure, whether or not substituted on the ring or group
668 structures to any extent; and
669 (III) Is a cannabinoid receptor agonist, unless
670 specifically excepted or unless listed in another schedule or
671 contained within a pharmaceutical product approved by the United
672 States Food and Drug Administration.
673 191. Substituted Cathinones.—Unless specifically excepted,
674 listed in another schedule, or contained within a pharmaceutical
675 product approved by the United States Food and Drug
676 Administration, any material, compound, mixture, or preparation,
677 including its salts, isomers, esters, or ethers, and salts of
678 isomers, esters, or ethers, whenever the existence of such salts
679 is possible within any of the following specific chemical
680 designations:
681 a. Any compound containing a 2-amino-1-phenyl-1-propanone
682 structure;
683 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
684 structure; or
685 c. Any compound containing a 2-amino-1-thiophenyl-1
686 propanone structure,
687
688 whether or not the compound is further modified:
689 (I) With or without substitution on the ring system to any
690 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
691 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
692 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
693 substituents;
694 (II) With or without substitution at the 3-propanone
695 position with an alkyl substituent or removal of the methyl
696 group at the 3-propanone position;
697 (III) With or without substitution at the 2-amino nitrogen
698 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
699 not further substituted in the ring system; or
700 (IV) With or without inclusion of the 2-amino nitrogen atom
701 in a cyclic structure, including, but not limited to:
702 (A) Methcathinone.
703 (B) Ethcathinone.
704 (C) Methylone (3,4-Methylenedioxymethcathinone).
705 (D) 2,3-Methylenedioxymethcathinone.
706 (E) MDPV (3,4-Methylenedioxypyrovalerone).
707 (F) Methylmethcathinone.
708 (G) Methoxymethcathinone.
709 (H) Fluoromethcathinone.
710 (I) Methylethcathinone.
711 (J) Butylone (3,4-Methylenedioxy-alpha
712 methylaminobutyrophenone).
713 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
714 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
715 (M) Naphyrone (Naphthylpyrovalerone).
716 (N) Bromomethcathinone.
717 (O) Buphedrone (alpha-Methylaminobutyrophenone).
718 (P) Eutylone (3,4-Methylenedioxy-alpha
719 ethylaminobutyrophenone).
720 (Q) Dimethylcathinone.
721 (R) Dimethylmethcathinone.
722 (S) Pentylone (3,4-Methylenedioxy-alpha
723 methylaminovalerophenone).
724 (T) Pentedrone (alpha-Methylaminovalerophenone).
725 (U) MDPPP (3,4-Methylenedioxy-alpha
726 pyrrolidinopropiophenone).
727 (V) MDPBP (3,4-Methylenedioxy-alpha
728 pyrrolidinobutyrophenone).
729 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
730 (X) PPP (Pyrrolidinopropiophenone).
731 (Y) PVP (Pyrrolidinovalerophenone) or
732 (Pyrrolidinopentiophenone).
733 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
734 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
735 (BB) F-MABP (Fluoromethylaminobutyrophenone).
736 (CC) Me-EABP (Methylethylaminobutyrophenone).
737 (DD) PBP (Pyrrolidinobutyrophenone).
738 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
739 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
740 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
741 (HH) Dimethylone (3,4-Methylenedioxy-N,N
742 dimethylcathinone).
743 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
744 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
745 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
746 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
747 (MM) Methylbuphedrone (Methyl-alpha
748 methylaminobutyrophenone).
749 (NN) Methyl-alpha-methylaminohexanophenone.
750 (OO) N-Ethyl-N-methylcathinone.
751 (PP) PHP (Pyrrolidinohexanophenone).
752 (QQ) PV8 (Pyrrolidinoheptanophenone).
753 (RR) Chloromethcathinone.
754 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
755 192. Substituted Phenethylamines.—Unless specifically
756 excepted or unless listed in another schedule, or contained
757 within a pharmaceutical product approved by the United States
758 Food and Drug Administration, any material, compound, mixture,
759 or preparation, including its salts, isomers, esters, or ethers,
760 and salts of isomers, esters, or ethers, whenever the existence
761 of such salts is possible within any of the following specific
762 chemical designations, any compound containing a phenethylamine
763 structure, without a beta-keto group, and without a benzyl group
764 attached to the amine group, whether or not the compound is
765 further modified with or without substitution on the phenyl ring
766 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
767 halide, fused alkylenedioxy, fused furan, fused benzofuran,
768 fused dihydrofuran, or fused tetrahydropyran substituents,
769 whether or not further substituted on a ring to any extent, with
770 or without substitution at the alpha or beta position by any
771 alkyl substituent, with or without substitution at the nitrogen
772 atom, and with or without inclusion of the 2-amino nitrogen atom
773 in a cyclic structure, including, but not limited to:
774 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
775 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
776 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
777 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
778 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
779 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
780 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
781 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
782 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
783 j. 2C-H (2,5-Dimethoxyphenethylamine).
784 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
785 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
786 m. MDMA (3,4-Methylenedioxymethamphetamine).
787 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
788 Methylenedioxy-N-methylbutanamine).
789 o. MDA (3,4-Methylenedioxyamphetamine).
790 p. 2,5-Dimethoxyamphetamine.
791 q. Fluoroamphetamine.
792 r. Fluoromethamphetamine.
793 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
794 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
795 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
796 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
797 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
798 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
799 y. PMA (4-Methoxyamphetamine).
800 z. N-Ethylamphetamine.
801 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
802 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
803 cc. PMMA (4-Methoxymethamphetamine).
804 dd. N,N-Dimethylamphetamine.
805 ee. 3,4,5-Trimethoxyamphetamine.
806 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
807 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
808 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
809 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
810 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
811 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
812 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
813 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
814 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
815 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
816 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
817 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
818 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
819 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
820 dihydrobenzofuran),
821
822 which does not include phenethylamine, mescaline as described in
823 subparagraph 20., substituted cathinones as described in
824 subparagraph 191., N-Benzyl phenethylamine compounds as
825 described in subparagraph 193., or methamphetamine as described
826 in subparagraph (2)(c)4.
827 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
828 excepted or unless listed in another schedule, or contained
829 within a pharmaceutical product approved by the United States
830 Food and Drug Administration, any material, compound, mixture,
831 or preparation, including its salts, isomers, esters, or ethers,
832 and salts of isomers, esters, or ethers, whenever the existence
833 of such salts is possible within any of the following specific
834 chemical designations, any compound containing a phenethylamine
835 structure without a beta-keto group, with substitution on the
836 nitrogen atom of the amino group with a benzyl substituent, with
837 or without substitution on the phenyl or benzyl ring to any
838 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
839 alkylenedioxy, fused furan, fused benzofuran, or fused
840 tetrahydropyran substituents, whether or not further substituted
841 on a ring to any extent, with or without substitution at the
842 alpha position by any alkyl substituent, including, but not
843 limited to:
844 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
845 methoxybenzyl)]phenethylamine).
846 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
847 hydroxybenzyl)]phenethylamine).
848 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
849 fluorobenzyl)]phenethylamine).
850 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
851 methylenedioxybenzyl)]phenethylamine).
852 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
853 methoxybenzyl)]phenethylamine).
854 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
855 hydroxybenzyl)]phenethylamine).
856 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
857 fluorobenzyl)]phenethylamine).
858 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
859 methylenedioxybenzyl)]phenethylamine).
860 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
861 methoxybenzyl)]phenethylamine).
862 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
863 methoxybenzyl)]phenethylamine).
864 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
865 methoxybenzyl)]phenethylamine).
866 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
867 methoxybenzyl)]phenethylamine).
868 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
869 hydroxybenzyl)]phenethylamine).
870 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
871 fluorobenzyl)]phenethylamine).
872 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
873 methylenedioxybenzyl)]phenethylamine).
874 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
875 methoxybenzyl)]phenethylamine).
876 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
877 hydroxybenzyl)]phenethylamine).
878 r. 25H-NBF (2,5-Dimethoxy-[N-(2
879 fluorobenzyl)]phenethylamine).
880 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
881 methoxybenzyl)]phenethylamine),
882
883 which does not include substituted cathinones as described in
884 subparagraph 191.
885 194. Substituted Tryptamines.—Unless specifically excepted
886 or unless listed in another schedule, or contained within a
887 pharmaceutical product approved by the United States Food and
888 Drug Administration, any material, compound, mixture, or
889 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
890 example tryptamine, structure with or without mono- or di
891 substitution of the amine nitrogen with alkyl or alkenyl groups,
892 or by inclusion of the amino nitrogen atom in a cyclic
893 structure, whether or not substituted at the alpha position with
894 an alkyl group, whether or not substituted on the indole ring to
895 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
896 groups, including, but not limited to:
897 a. Alpha-Ethyltryptamine.
898 b. Bufotenine.
899 c. DET (Diethyltryptamine).
900 d. DMT (Dimethyltryptamine).
901 e. MET (N-Methyl-N-ethyltryptamine).
902 f. DALT (N,N-Diallyltryptamine).
903 g. EiPT (N-Ethyl-N-isopropyltryptamine).
904 h. MiPT (N-Methyl-N-isopropyltryptamine).
905 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
906 j. 5-Hydroxy-N-methyltryptamine.
907 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
908 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
909 m. Methyltryptamine.
910 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
911 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
912 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
913 q. DiPT (N,N-Diisopropyltryptamine).
914 r. DPT (N,N-Dipropyltryptamine).
915 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
916 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
917 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
918 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
919 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
920 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
921 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
922 isopropyltryptamine).
923 z. Methyl-alpha-ethyltryptamine.
924 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
925
926 which does not include tryptamine, psilocyn as described in
927 subparagraph 34., or psilocybin as described in subparagraph 33.
928 195. Substituted Phenylcyclohexylamines.—Unless
929 specifically excepted or unless listed in another schedule, or
930 contained within a pharmaceutical product approved by the United
931 States Food and Drug Administration, any material, compound,
932 mixture, or preparation containing a phenylcyclohexylamine
933 structure, with or without any substitution on the phenyl ring,
934 any substitution on the cyclohexyl ring, any replacement of the
935 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
936 without substitution on the amine with alkyl, dialkyl, or alkoxy
937 substituents, inclusion of the nitrogen in a cyclic structure,
938 or any combination of the above, including, but not limited to:
939 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
940 (Benocyclidine).
941 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
942 of phencyclidine).
943 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
944 analog of phencyclidine).
945 d. PCPr (Phenylcyclohexylpropylamine).
946 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
947 analog of phencyclidine).
948 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
949 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
950 h. Methoxetamine.
951 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
952 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
953 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
954 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
955 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
956 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
957 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
958 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
959 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
960 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
961 196. CBD (Cannabidiol).
962 Section 2. This act shall take effect July 1, 2017.
